Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Vitamin D Supplementation in Children With Sickle Cell Disease (VIDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04662476
Recruitment Status : Unknown
Verified April 2021 by College of Health Sciences, Makerere University.
Recruitment status was:  Not yet recruiting
First Posted : December 10, 2020
Last Update Posted : April 13, 2021
Information provided by (Responsible Party):
College of Health Sciences, Makerere University

Brief Summary:
Children aged 6 months to 12 years of age will be randomised to receive vitamin D 60,000IU once a month for 3 months or a placebo. The vitamin D will be in form of granules supplied in sachets. The primary study outcomes will be incidence of hospitalisation and change in vitamin D levels following supplementation. Secondary outcomes will include incidence of vaso-occlusive crisis (VOC), acute severe respiratory illness, Vitamin D related Severe adverse events and requirements for blood transfusion

Condition or disease Intervention/treatment Phase
Children With Sickle Cell Disease at Mulago Hospital Dietary Supplement: Vitamin D3 Not Applicable

Detailed Description:

BACKGROUND: More than 75% of all children with sickle cell anemia (SCA) are born in sub-Saharan Africa annually. The hallmark of SCA is haemolytic anaemia and or pain crisis that often require hospitalisation. Interventions to reduce the complications, which are prerequisites for frequent hospitalisations, are needed urgently. Vitamin D deficiency is common in children with SCA and is associated with recurrent vaso-occlusive crisis, blood transfusion, hospitalisation and infections. Routine vitamin D supplementation is not practiced in the care of sickle cell disease patients yet it has been associated with improved bone health and bone mineral density, reduced chronic pain and improved quality of life.

HYPOTHESIS: Vitamin D supplementation will lead to a lower incidence of hospitalisation than placebo in Ugandan children with SCA.

METHODS: The study will be a randomized, placebo-controlled, double blind clinical trial in which 331 Ugandan children with SCA aged 6 months to 12 years inclusive will receive vitamin D (60,000IU granules monthly) and another 331 a placebo (identical to vitaminD in appearance) for 3 months. The primary study outcome will be incidence of hospitalisation. Secondary outcomes will include incidence of vaso-occlusive crisis (VOC), acute severe respiratory illness, Vitamin D related Severe adverse events and requirements for blood transfusion IMPACT: If this trial shows a reduction in hospitalisation, it will be the basis for a multi-site pre-post intervention clinical trial to assess real-world safety and efficacy of Vitamin D in African children with SCA. The monthly administration is easy, and since vitamin D is inexpensive, this trial has the potential to improve the health of hundreds/ thousands of African children with SCA through reduction of infection-related morbidity and mortality.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 662 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 331 children will be randomised to the intervention and another 331 to the placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The sachets containing vitamin D will be exactly similar to the ones containing the placebo. Both the intervention and placebo granules will be identical in colour, odour, taste and amount. Children will be randomized into treatment groups by order of entry in the study, based on a pre-determined blinded randomization list created and managed by an independent statistician.
Primary Purpose: Treatment
Official Title: Effect of Vitamin D Supplementation on Sickle Cell Disease Hospitalisation and Related Complications Among Children in Mulago Hospital: A Randomised Clinical Trial
Estimated Study Start Date : May 17, 2021
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : January 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Active Comparator: Vitamin D supplement
331 children will each received 60,000IU of vitamin D once a month for 3 months.
Dietary Supplement: Vitamin D3
Vitamin D3 supplement

Active Comparator: Intervention
The intervention arm will receive vitamin D3.
Dietary Supplement: Vitamin D3
Vitamin D3 supplement

Primary Outcome Measures :
  1. Frequency of hospitalisation among children with SCD supplemented with vitamin D versus placebo. [ Time Frame: 3 months follow up ]
    Number of children hospitalised during the follow up period and number of hospitalisations per child

  2. Effect of vitamin supplementation on serum levels of 25 Hydroxyvitamin D levels in children with SCD [ Time Frame: 3 months follow up ]
    Serum levels of 25 Hydroxyvitamin D

  3. Frequency of blood transfusion among children supplemented with vitamin D versus Placebo in children with sickle cell anaemia [ Time Frame: 3 months follow up ]
    The number of children requiring blood transfusion during follow up and the episodes per child

Secondary Outcome Measures :
  1. Incidence of vaso-occlusive crises (VOC) [ Time Frame: 3 months follow up ]
    Incidence of painful vaso-occlusive crises

  2. Incidence of acute severe respiratory illnesses [ Time Frame: 3 months follow up ]
    Incidence of cough associated with difficult breathing confirmed as pneumonia or acute chest syndrome by a health worker

  3. Severe adverse events [ Time Frame: 3 months follow up ]
    Serious adverse events for example severe diarrhoea and vomiting with dehydration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented sickle cell disease (HbSS supported by hemoglobin electrophoresis results) attending Mulago Hospital Sickle Cell Clinic)
  2. Age range of 6 months to 12 years, inclusive, at the time of enrolment
  3. Weight at least 5.0 kg at the time of enrolment
  4. Willingness to comply with all study-related treatments, evaluations, and follow-up

Exclusion Criteria:

  1. Known other chronic medical condition (e.g., HIV, malignancy, Renal & liver disease, active clinical tuberculosis)
  2. Severe acute malnutrition determined by impaired growth parameters as defined by WHO weight for length/height less than -3SD.
  3. Evidence of Vitamin D supplementation in the past one month (by prescription or drug sample)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04662476

Layout table for location contacts
Contact: Grace Ndeezi, PhD +256 772453191
Contact: Ruth Namazzi, MMED +256 772356331

Sponsors and Collaborators
Makerere University
Layout table for investigator information
Principal Investigator: Grace Ndeezi, PhD Makerere University, Kampala, Uganda
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: College of Health Sciences, Professor, Makerere University Identifier: NCT04662476    
Other Study ID Numbers: 2020-117
First Posted: December 10, 2020    Key Record Dates
Last Update Posted: April 13, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant information may be shared with other researchers.
Supporting Materials: Clinical Study Report (CSR)
Time Frame: within one year and the sharing period could extend beyond this period
Access Criteria: If requested by other researchers who have carried out similar studies for a meta-analysis

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Vitamin D
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents